BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24704000)

  • 1. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
    Tulsyan S; Chaturvedi P; Singh AK; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
    Gene; 2014 Jun; 543(1):69-75. PubMed ID: 24704000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ABCB1 genetic variants in breast cancer treatment outcomes.
    Chaturvedi P; Tulsyan S; Agarwal G; Lal P; Agarwal S; Mittal RD; Mittal B
    Cancer Epidemiol; 2013 Oct; 37(5):754-61. PubMed ID: 23707158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
    Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
    Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.
    Agarwal G; Tulsyan S; Lal P; Mittal B
    World J Surg; 2016 Jul; 40(7):1600-10. PubMed ID: 26506825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.
    Tulsyan S; Agarwal G; Lal P; Mittal B
    Clin Chim Acta; 2014 Jul; 434():21-8. PubMed ID: 24768782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
    Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
    Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
    Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
    Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach.
    Tulsyan S; Chaturvedi P; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
    Mol Diagn Ther; 2013 Dec; 17(6):371-9. PubMed ID: 23812950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
    Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
    Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
    Chang H; Rha SY; Jeung HC; Im CK; Ahn JB; Kwon WS; Yoo NC; Roh JK; Chung HC
    Ann Oncol; 2009 Feb; 20(2):272-7. PubMed ID: 18836089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy.
    Chang H; Rha SY; Jeung HC; Im CK; Noh SH; Kim JJ; Chung HC
    Oncol Rep; 2010 Jan; 23(1):271-8. PubMed ID: 19956892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Han SW; Jeon YK; Oh DY; Han W; Kim TY; Park IA; Noh DY; Bang YJ
    Oncology; 2012; 83(4):218-27. PubMed ID: 22906996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
    Kim HJ; Im SA; Keam B; Ham HS; Lee KH; Kim TY; Kim YJ; Oh DY; Kim JH; Han W; Jang IJ; Kim TY; Park IA; Noh DY
    Cancer Sci; 2015 Jan; 106(1):86-93. PubMed ID: 25410489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
    Vaclavikova R; Nordgard SH; Alnaes GI; Hubackova M; Kubala E; Kodet R; Mrhalova M; Novotny J; Gut I; Kristensen VN; Soucek P
    Pharmacogenet Genomics; 2008 Mar; 18(3):263-73. PubMed ID: 18300948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
    Lévy P; Gligorov J; Antoine M; Rezai K; Lévy E; Selle F; Saintigny P; Lokiec F; Avenin D; Beerblock K; Lotz JP; Bernaudin JF; Fajac A
    Breast Cancer Res Treat; 2013 Jun; 139(2):421-8. PubMed ID: 23666532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
    Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
    Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
    Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
    Ikeda M; Tsuji D; Yamamoto K; Kim YI; Daimon T; Iwabe Y; Hatori M; Makuta R; Hayashi H; Inoue K; Nakamichi H; Shiokawa M; Itoh K
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):149-53. PubMed ID: 25989890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
    Choi JR; Kim JO; Kang DR; Shin JY; Zhang XH; Oh JE; Park JY; Kim KA; Kang JH
    Cancer Res Treat; 2015 Jul; 47(3):509-17. PubMed ID: 25648089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
    Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN
    Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.